top of page

BIO 2026: AltruBio believes that its PSGL-1, a T-cell checkpoint targeting antibody, could be a "ceiling raiser" in the I&I space

  • 1 day ago
  • 1 min read

Chair and CEO Judy Chou describes the science behind the target (this is the company's second generation molecule), and discusses the current clinical program in UC. She believes they have a "best in disease outcome" medicine and says they have talked to all the key players in I&I regarding a potential collaboration.




Coverage brought to you by



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page